论文部分内容阅读
国外一些企业已经公布丁它们的1998年一季度业绩。 默克公司1998年一季度开端很好,新产品的重要增长点是抗高血脂药物Zocor(辛伐他丁)、抗高血压药物、血管紧张素Ⅱ抑制剂Cozaar(洛沙坦)、骨质疏松症治疗药物Fosamax(阿仑膦酸钠)。 一季度默克公司的销售增长9％,达到61亿美元,纯利润增长了14％,达到12亿美元。收入增长12％,包括植物保护业务脱钩,和建立Merial合资企业的费用。 默克公司在海外的销售比例从去年同期的29％下降到今年一季度的25％。 Zocor的销售增长9％,达到8.75亿美元,Zocor和
Some foreign companies have announced their first-quarter results in 1998. Merck started well in the first quarter of 1998. The important growth points for new products are anti-hyperlipidemic drugs Zocor (simvastatin), anti-hypertensive drugs, angiotensin II inhibitor Cozaar (Losartan), and bone mass. Osteoporosis treatment drug Fosamax (alendronate sodium). In the first quarter, Merck’s sales increased by 9% to US$6.1 billion, and net profit increased by 14% to US$1.2 billion. Revenue increased by 12%, including the decoupling of the plant protection business, and the establishment of a Merial joint venture. Merck’s overseas sales ratio dropped from 29% in the same period last year to 25% in the first quarter of this year. Zocor’s sales increased 9% to $875 million, with Zocor and